The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19
The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in...
Saved in:
| Published in | Current controlled trials in cardiovascular medicine Vol. 23; no. 1; pp. 158 - 17 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
16.02.2022
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1745-6215 1745-6215 |
| DOI | 10.1186/s13063-022-06055-9 |
Cover
Loading…
| Abstract | The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact.
This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics.
The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay.
Protocol version and date: V3.1, 16 April 2021. Recruitment started on 09 March 2021. Estimated recruitment period of approximately 40 weeks.
ClinicalTrials.gov NCT04794088 . Registered on 11 March 2021. |
|---|---|
| AbstractList | Background The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact. Methods This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics. Discussion The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay. Trial status Protocol version and date: V3.1, 16 April 2021. Recruitment started on 09 March 2021. Estimated recruitment period of approximately 40 weeks. Trial registration ClinicalTrials.govNCT04794088. Registered on 11 March 2021. Keywords: COVID-19, Randomized controlled trial, Protocol, ARDS, Imatinib, Extravascular lung water, Vascular permeability, Endothelial dysfunction Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact. Methods This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics. Discussion The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay. Trial status Protocol version and date: V3.1, 16 April 2021. Recruitment started on 09 March 2021. Estimated recruitment period of approximately 40 weeks. Trial registration ClinicalTrials.gov NCT04794088 . Registered on 11 March 2021. The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact.BACKGROUNDThe coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact.This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics.METHODSThis is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics.The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay.DISCUSSIONThe current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay.Protocol version and date: V3.1, 16 April 2021. Recruitment started on 09 March 2021. Estimated recruitment period of approximately 40 weeks.TRIAL STATUSProtocol version and date: V3.1, 16 April 2021. Recruitment started on 09 March 2021. Estimated recruitment period of approximately 40 weeks.ClinicalTrials.gov NCT04794088 . Registered on 11 March 2021.TRIAL REGISTRATIONClinicalTrials.gov NCT04794088 . Registered on 11 March 2021. The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact. This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics. The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay. Protocol version and date: V3.1, 16 April 2021. Recruitment started on 09 March 2021. Estimated recruitment period of approximately 40 weeks. ClinicalTrials.gov NCT04794088 . Registered on 11 March 2021. The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact. This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics. The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay. BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact.MethodsThis is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics.DiscussionThe current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay.Trial statusProtocol version and date: V3.1, 16 April 2021. Recruitment started on 09 March 2021. Estimated recruitment period of approximately 40 weeks.Trial registrationClinicalTrials.govNCT04794088. Registered on 11 March 2021. |
| ArticleNumber | 158 |
| Audience | Academic |
| Author | Bartelink, Imke H. Bogaard, Harm Jan Snape, Sue D. Heunks, Leo Aman, Jurjan Atmowihardjo, Leila van Rein, Nienke Purdy, Keith Cavalla, David Bet, Pierre M. Juffermans, Nicole Schippers, Job R. McElroy, Andrew Schultz, Marcus Tuinman, Pieter R. Bos, Lieuwe D. J. Comberiati, Valérie |
| Author_xml | – sequence: 1 givenname: Leila orcidid: 0000-0002-7452-1867 surname: Atmowihardjo fullname: Atmowihardjo, Leila – sequence: 2 givenname: Job R. surname: Schippers fullname: Schippers, Job R. – sequence: 3 givenname: Imke H. surname: Bartelink fullname: Bartelink, Imke H. – sequence: 4 givenname: Pierre M. surname: Bet fullname: Bet, Pierre M. – sequence: 5 givenname: Nienke surname: van Rein fullname: van Rein, Nienke – sequence: 6 givenname: Keith surname: Purdy fullname: Purdy, Keith – sequence: 7 givenname: David surname: Cavalla fullname: Cavalla, David – sequence: 8 givenname: Valérie surname: Comberiati fullname: Comberiati, Valérie – sequence: 9 givenname: Andrew surname: McElroy fullname: McElroy, Andrew – sequence: 10 givenname: Sue D. surname: Snape fullname: Snape, Sue D. – sequence: 11 givenname: Harm Jan surname: Bogaard fullname: Bogaard, Harm Jan – sequence: 12 givenname: Leo surname: Heunks fullname: Heunks, Leo – sequence: 13 givenname: Nicole surname: Juffermans fullname: Juffermans, Nicole – sequence: 14 givenname: Marcus surname: Schultz fullname: Schultz, Marcus – sequence: 15 givenname: Pieter R. surname: Tuinman fullname: Tuinman, Pieter R. – sequence: 16 givenname: Lieuwe D. J. surname: Bos fullname: Bos, Lieuwe D. J. – sequence: 17 givenname: Jurjan surname: Aman fullname: Aman, Jurjan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35172891$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9U0tuFDEQbaEg8oELsECW2IRFB3-6PW0WkaIQYKQo2YRsLbc_E4-624PtDmoOxSE4D4egZiZBSYSQF7Zc7z3XK1ftFztDGGxRvCb4iJCGv0-EYc5KTGmJOa7rUjwr9sisqktOSb3z4Lxb7Ke0xLhiglUvil1WkxltBNkrfl_dWDS_uD67uEKnl9fzjyhHr7oPSKGU46jzGK1Bqxhy0KFDLkSIRDWY0PsfENFhyDF0HRw3ROSHW5uyX6jshwXKoG6d81rpCQELJeVsnlBwAMxR3dohjAn5fg33LeptmjqVLTqc9ysLCP_r5zuAojS2S6tzQt99vkFKj4CJNq18VDnECRkP6dqUUJoGE0NvgWRGDWm109ZYScTL4rlTXbKv7vaD4uuns6vTL-X55ef56cl5qWvOcqmYwc7xihOiobiMVpWoCaXWNLVoOK2JcMRaDuXVGNPZrOKaKqcE5YpoYdhBMd_qmqCWchXBXpxkUF5uLkJcSBWz152VdGZa01YzMxOmUhgL6pxjLWtqbivCatA63mqtxra3Rq-LorpHoo8jg7-Ri3Arm6ZqREVB4PBOIIZvI_yN7H3StuvUYKH2knIKpjAnHKBvn0CXYYwDlAryZJhVNd1kdIdaKDDgBxfgXb0WlSdciKoWol4_e_QPFCxjew9dY52H-0eENw-N_nV436sAaLYAHUNK0TqpfYa-WXeg8p0kWK7HQm7HQsLPyc1YSAFU-oR6r_4f0h9WehJw |
| CitedBy_id | crossref_primary_10_1002_psp4_13299 crossref_primary_10_1186_s13054_023_04516_4 crossref_primary_10_3390_covid3070070 crossref_primary_10_1183_23120541_00532_2022 crossref_primary_10_1016_j_antiviral_2025_106101 crossref_primary_10_1152_ajplung_00196_2024 crossref_primary_10_1161_CIRCRESAHA_122_322332 crossref_primary_10_3390_cancers15112972 |
| Cites_doi | 10.1161/CIRCULATIONAHA.112.134304 10.1016/j.bja.2017.11.095 10.1186/2110-5820-3-25 10.1164/rccm.200508-1302OC 10.1172/JCI60331 10.1056/NEJM200005043421801 10.1200/JCO.2011.35.6733 10.1080/0284186X.2018.1479072 10.1056/NEJMoa1800385 10.1186/cc12539 10.1159/000327719 10.1152/ajplung.00323.2014 10.1164/rccm.201003-0423OC 10.1177/0091270003262101 10.1056/NEJMoa1215554 10.1186/cc12786 10.1164/rccm.201301-0136LE 10.1016/S2213-2600(20)30328-3 10.1056/NEJMoa1214103 10.1371/journal.pone.0085231 10.1007/s10456-021-09808-3 10.1001/jama.2012.5669 10.1001/jama.2020.12839 10.1097/00003246-199908000-00006 10.7196/SAJCC.148 10.1007/s00228-009-0621-z 10.1152/ajpheart.00922.2003 10.1186/s13613-014-0027-7 10.1056/NEJMoa1005372 10.1183/09031936.00054407 10.1186/2052-0492-2-25 10.1007/s00262-010-0966-2 10.1182/blood-2006-04-018705 10.1016/S2213-2600(17)30188-1 10.1001/jama.2020.2648 10.1056/NEJMoa062200 10.1161/ATVBAHA.115.305085 10.14814/phy2.12589 10.1182/blood.V90.9.3691 |
| ContentType | Journal Article |
| Copyright | 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2022 |
| Copyright_xml | – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-022-06055-9 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_27dbdb47d79d4a0092fff3b3856e4135 PMC8848942 A699459952 35172891 10_1186_s13063_022_06055_9 |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | Netherlands |
| GeographicLocations_xml | – name: Netherlands |
| GrantInformation_xml | – fundername: Innovative Medicines Initiative grantid: 101005142 – fundername: ; grantid: 101005142 |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 5GY 7XB 8FK AHMBA AZQEC COVID DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c563t-a3d0ff64611c022324495122ed859862519f1ee6174c0027746c2afa926a1c9d3 |
| IEDL.DBID | M48 |
| ISSN | 1745-6215 |
| IngestDate | Wed Aug 27 01:33:13 EDT 2025 Thu Aug 21 18:10:27 EDT 2025 Mon Jul 21 10:25:42 EDT 2025 Fri Jul 25 19:47:36 EDT 2025 Tue Jun 17 21:00:32 EDT 2025 Tue Jun 10 20:08:10 EDT 2025 Mon Jul 21 06:04:35 EDT 2025 Tue Jul 01 04:01:02 EDT 2025 Thu Apr 24 22:59:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 Extravascular lung water Imatinib Endothelial dysfunction Protocol Randomized controlled trial Vascular permeability ARDS |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c563t-a3d0ff64611c022324495122ed859862519f1ee6174c0027746c2afa926a1c9d3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Undefined-1 content type line 23 |
| ORCID | 0000-0002-7452-1867 |
| OpenAccessLink | https://www.proquest.com/docview/2730345235?pq-origsite=%requestingapplication% |
| PMID | 35172891 |
| PQID | 2730345235 |
| PQPubID | 44365 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_27dbdb47d79d4a0092fff3b3856e4135 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8848942 proquest_miscellaneous_2629860616 proquest_journals_2730345235 gale_infotracmisc_A699459952 gale_infotracacademiconefile_A699459952 pubmed_primary_35172891 crossref_citationtrail_10_1186_s13063_022_06055_9 crossref_primary_10_1186_s13063_022_06055_9 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-16 |
| PublicationDateYYYYMMDD | 2022-02-16 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2022 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | J Aman (6055_CR3) 2012; 126 J Aman (6055_CR5) 2013; 188 H Shi (6055_CR38) 2020; S1473-3099 MJ Overbeek (6055_CR30) 2008; 32 World Health Organization (6055_CR43) 2020 6055_CR15 S Mumprecht (6055_CR28) 2006; 108 6055_CR34 6055_CR14 M Schmidt (6055_CR37) 2020; 8 MA Matthay (6055_CR25) 2012; 122 T Tagami (6055_CR41) 2014; 4 N Kurimoto (6055_CR20) 2004; 287 JC Montejo (6055_CR27) 1999; 27 ARDS Network (6055_CR1) 2000; 342 MK Langberg (6055_CR22) 2018; 57 RS Stephens (6055_CR40) 2015; 3 WJ Wiersinga (6055_CR42) 2020; 324 ARDS Definition Task Force (6055_CR6) 2012; 307 LT Hill (6055_CR16) 2013; 29 F Carnevale-Schianca (6055_CR8) 2011; 29 ND Ferguson (6055_CR13) 2013; 368 J Amado-Azevedo (6055_CR2) 2021; 26 GD Perkins (6055_CR33) 2006; 173 6055_CR29 AN Rizzo (6055_CR36) 2015; 35 MW Deininger (6055_CR12) 1997; 90 S Kushimoto (6055_CR21) 2013; 17 6055_CR44 LM Brown (6055_CR7) 2013; 3 A Combes (6055_CR10) 2018; 378 E Letsiou (6055_CR23) 2015; 308 6055_CR4 TR Craig (6055_CR11) 2011; 183 T Kaneko (6055_CR17) 2014; 2 L Papazian (6055_CR31) 2010; 363 IK Kim (6055_CR18) 2013; 17 MA Matthay (6055_CR26) 2017; 5 B Peng (6055_CR32) 2004; 44 N Singh (6055_CR39) 2009; 65 EM Chislock (6055_CR9) 2013; 8 R Maggio (6055_CR24) 2011; 60 CK Rhee (6055_CR35) 2011; 82 NJ Koning (6055_CR19) 2018; 120 |
| References_xml | – volume: 126 start-page: 2728 issue: 23 year: 2012 ident: 6055_CR3 publication-title: Circulation. doi: 10.1161/CIRCULATIONAHA.112.134304 – volume: 120 start-page: 1165 issue: 6 year: 2018 ident: 6055_CR19 publication-title: Br J Anaesth. doi: 10.1016/j.bja.2017.11.095 – volume: 3 start-page: 25 issue: 1 year: 2013 ident: 6055_CR7 publication-title: Ann Intens Care. doi: 10.1186/2110-5820-3-25 – volume: 173 start-page: 281 issue: 3 year: 2006 ident: 6055_CR33 publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.200508-1302OC – volume: 122 start-page: 2731 issue: 8 year: 2012 ident: 6055_CR25 publication-title: J Clin Invest. doi: 10.1172/JCI60331 – volume: 342 start-page: 1301 issue: 18 year: 2000 ident: 6055_CR1 publication-title: N Engl J Med. doi: 10.1056/NEJM200005043421801 – volume: 29 start-page: e691 issue: 24 year: 2011 ident: 6055_CR8 publication-title: J Clin Oncol. doi: 10.1200/JCO.2011.35.6733 – volume: 57 start-page: 1401 issue: 10 year: 2018 ident: 6055_CR22 publication-title: Acta Oncol. doi: 10.1080/0284186X.2018.1479072 – volume: 378 start-page: 1965 issue: 21 year: 2018 ident: 6055_CR10 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1800385 – volume: S1473-3099 start-page: 30086 issue: 20 year: 2020 ident: 6055_CR38 publication-title: Lancet Infect Dis – volume: 17 start-page: 418 issue: 2 year: 2013 ident: 6055_CR21 publication-title: Crit Care. doi: 10.1186/cc12539 – volume: 82 start-page: 273 issue: 3 year: 2011 ident: 6055_CR35 publication-title: Respiration doi: 10.1159/000327719 – volume: 308 start-page: L259 issue: 3 year: 2015 ident: 6055_CR23 publication-title: Am J Physiol Lung Cell Mol Physiol. doi: 10.1152/ajplung.00323.2014 – volume: 183 start-page: 620 issue: 5 year: 2011 ident: 6055_CR11 publication-title: Am J Respir Crit Care Med. doi: 10.1164/rccm.201003-0423OC – volume: 44 start-page: 158 issue: 2 year: 2004 ident: 6055_CR32 publication-title: J Clin Pharmacol. doi: 10.1177/0091270003262101 – ident: 6055_CR4 – volume: 368 start-page: 795 issue: 9 year: 2013 ident: 6055_CR13 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1215554 – volume: 17 start-page: R114 issue: 3 year: 2013 ident: 6055_CR18 publication-title: Crit Care. doi: 10.1186/cc12786 – volume: 188 start-page: 1171 issue: 9 year: 2013 ident: 6055_CR5 publication-title: American Journal of Respiratory and Critical Care Medicine doi: 10.1164/rccm.201301-0136LE – volume: 8 start-page: 1121 issue: 11 year: 2020 ident: 6055_CR37 publication-title: Lancet Respir Med. doi: 10.1016/S2213-2600(20)30328-3 – ident: 6055_CR15 doi: 10.1056/NEJMoa1214103 – volume: 8 start-page: e85231 year: 2013 ident: 6055_CR9 publication-title: PLoS ONE. doi: 10.1371/journal.pone.0085231 – volume: 26 start-page: 1 year: 2021 ident: 6055_CR2 publication-title: Angiogenesis. doi: 10.1007/s10456-021-09808-3 – ident: 6055_CR34 – volume: 307 start-page: 2526 issue: 23 year: 2012 ident: 6055_CR6 publication-title: JAMA. doi: 10.1001/jama.2012.5669 – volume: 324 start-page: 782 issue: 8 year: 2020 ident: 6055_CR42 publication-title: JAMA. doi: 10.1001/jama.2020.12839 – volume: 27 start-page: 1447 issue: 8 year: 1999 ident: 6055_CR27 publication-title: Crit Care Med. doi: 10.1097/00003246-199908000-00006 – volume: 29 start-page: 11 issue: 1 year: 2013 ident: 6055_CR16 publication-title: S Afr J Crit Care doi: 10.7196/SAJCC.148 – volume: 65 start-page: 545 issue: 6 year: 2009 ident: 6055_CR39 publication-title: Eur J Clin Pharmacol. doi: 10.1007/s00228-009-0621-z – volume: 287 start-page: H100 issue: 1 year: 2004 ident: 6055_CR20 publication-title: Am J Physiol Heart Circ Physiol. doi: 10.1152/ajpheart.00922.2003 – volume: 4 start-page: 27 issue: 1 year: 2014 ident: 6055_CR41 publication-title: Ann Intensive Care. doi: 10.1186/s13613-014-0027-7 – volume: 363 start-page: 1107 issue: 12 year: 2010 ident: 6055_CR31 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1005372 – volume: 32 start-page: 232 issue: 1 year: 2008 ident: 6055_CR30 publication-title: Eur Respir J. doi: 10.1183/09031936.00054407 – ident: 6055_CR14 – volume: 2 start-page: 25 issue: 1 year: 2014 ident: 6055_CR17 publication-title: J Intensive Care doi: 10.1186/2052-0492-2-25 – volume: 60 start-page: 599 issue: 4 year: 2011 ident: 6055_CR24 publication-title: Cancer Immunol Immunother. doi: 10.1007/s00262-010-0966-2 – volume: 108 start-page: 3406 issue: 10 year: 2006 ident: 6055_CR28 publication-title: Blood. doi: 10.1182/blood-2006-04-018705 – volume: 5 start-page: 524 issue: 6 year: 2017 ident: 6055_CR26 publication-title: Lancet Respir Med. doi: 10.1016/S2213-2600(17)30188-1 – ident: 6055_CR44 doi: 10.1001/jama.2020.2648 – ident: 6055_CR29 doi: 10.1056/NEJMoa062200 – volume: 35 start-page: 1071 issue: 5 year: 2015 ident: 6055_CR36 publication-title: Arterioscler Thromb Vasc Biol. doi: 10.1161/ATVBAHA.115.305085 – volume: 3 start-page: e12589 issue: pii year: 2015 ident: 6055_CR40 publication-title: Physiol Rep doi: 10.14814/phy2.12589 – volume-title: Novel Coronavirus COVID-19 Therapeutic Trial Synopsis year: 2020 ident: 6055_CR43 – volume: 90 start-page: 3691 issue: 9 year: 1997 ident: 6055_CR12 publication-title: Blood. doi: 10.1182/blood.V90.9.3691 |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.339504 |
| Snippet | The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory... Background The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute... BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute... Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 158 |
| SubjectTerms | Acute respiratory distress syndrome ARDS Clinical trials Coronaviruses COVID-19 Drug therapy Edema Epidemics Extravascular lung water Hospitalization Humans Imatinib Imatinib Mesylate - adverse effects Inhibitor drugs Mortality Multicenter Studies as Topic Patient outcomes Patients Permeability Protocol Randomized controlled trial Randomized Controlled Trials as Topic Respiratory distress syndrome Respiratory Distress Syndrome - diagnosis Respiratory failure Risk factors RNA, Viral SARS-CoV-2 Study Protocol Treatment Outcome Ventilators |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4p-FggYJCRCKunYcJ-ZWSqsuUpdLW_Vm2bFdIm2zqNk9LA_FQ_A8PAQzSXa7ERJcuG3WY8Xj-Twzju3PjL3m1uXCogWymI4TiQ-JiwVPspIrCvAxSjrgfDJVx2fy80V2sXXVF-0J6-iBu47bE7l33snc59pLSxRBMcbUpUWmAjrglr0UY956MtX5YIyyqVwfkSnUXoOeul2vFMkY8_cs0YMw1LL1_-mTt4LScMPkVgQ6usfu9qkj7HdNvs9uhfoBu33SL44_ZL_Q5DCZnh9OT-Hgy_nkE7RXcnwACx1L7PI6eCBihjlaHzBbxRIMVX5-VX3Hkn7X-gx_thWhuuHgqC8BM0UIRDhhyxVgLWhsDIsVzCMKLugWI2J7hYpS4LpycBWa1QwzWXg7wdQcJaqfP96hKDRLRx9_GqBvwGDLJcpc36z4g6-6AyywZlPASh4R6MGtOsUSrh-xs6PD04PjpL_MISkzlS4Sm_pxjEoqzku0A-ZxODXjQgRfEEU8HaCNPARMqGRJc-VcqlLYaLVQlpfap4_ZTj2vw1OGujrEnbJyHDLJXXBjHcepDk7xmJa5GDG-tq0pe6ZzunBjZtoZT6FMhweD7TAtHowesfebOt86no-_Sn8kyGwkiaO7_QORa3rkmn8hd8TeEOAMeRJsHlqvOxCBShInl9lXWkvig0OFdgeS6AHKYfEasqb3QA2-HZMTmQl6z6tNMdWkXXV1QEQYoQR2PWZ0asSedAjfqJRmdHOZ5iOWD7A_0HlYUldfW37yopCFluLZ_-ik5-yOaIetSLjaZTs4XMILTAMX7mU74n8D3UhddA priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELdgSIgXxH8CAxkJCRCKFjuOE_OCxti0Iq28bFPfLDu2R6QuHU37UD4UH4LPw4fgLknbRUh7a-uz5Oudz7_zn98R8pYZm3MDFshCmsQCvsQ2FCzOSiZxgQ9B4APnk7E8PhPfJtmk33Br-muV65jYBmo3K3GPfA-W2SQVkDZln69-xlg1Ck9X-xIat8kdpC7D5CufbBIulhdSrB_KFHKvgXjdnlryOAEUn8VqsBi1nP3_R-ZrS9Pw2uS1dejoAbnfA0i631n8Ibnl60fk7kl_RP6Y_AXD09H4_HB8Sg--n4--0rYwxydqaMcVu5x7R5GeYQY-QAGzQgssWG52Wf2Clv7u-hQ-th1ptWXiqC8o4EXqkXbClCsKvWhjgl-s6CyA4AJrGSHnK60QCNeVpZe-WU0Bz9L3IwDoIFH9-f0BRGmztLgF1FDcCaamXILMfHvuT13VPWOha04F6OTADx21q06xmKkn5Ozo8PTgOO5LOsRlJtNFbFKXhCCFZKwEOwCagwSNce5dgUTx-Iw2MO8BVokSM-ZcyJKbYBSXhpXKpU_JTj2r_XMCulrwPmlE4jPBrLeJCkmqvJUspGXOI8LWttVlz3eOZTemus17Cqk7f9AwDt36g1YR-bjpc9Wxfdwo_QVdZiOJTN3tD7P5he4nvua5s86K3OXKCYMUVyGE1KZFJj0AiCwi79DhNMYTGB5Yr3sWAUoiM5fel0oJZIUDhXYHkhAHymHz2mV1H4cavZ01EXmzacaeeLeu9uARmksOfz3gOhmRZ52Hb1RKM6xfplhE8oHvD3QettTVj5alvChEoQR_cfOwXpJ7vJ2QPGZyl-zARPCvAOYt7Ot2Lv8DLYZUxw priority: 102 providerName: ProQuest |
| Title | The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35172891 https://www.proquest.com/docview/2730345235 https://www.proquest.com/docview/2629860616 https://pubmed.ncbi.nlm.nih.gov/PMC8848942 https://doaj.org/article/27dbdb47d79d4a0092fff3b3856e4135 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3rbtMwFLZ2kab9QdwpjMpISIBQWOw4ToKEUDc61kotCLap_6I4tkekLoWmlSgPxUPwPDwE5-TSLWLwpzcfN3H8HZ_Pif0dQp6yRAU8gR7wrec6Ar44yobM8VMmMcBbK3CD82gsj0_FcOJPNkiT7qi-gMW1UzvMJ3U6n776_m31Fhz-TenwodwvYBwun0ZyxwV27jvRJtmGyBRgKoeRWD9VgNjriWbjzLX1dsmO52PGpoi14lQp5__3oH0larVXVF4JUUc3yY2aW9JeBYZbZMPkt8nOqH56fof8BkzQwfisPz6hhx_OBu9ombPjNU1oJSO7nBtNUblhBvCgQGehBGKZnl1kP6CkXtY-hY9lRZpdinTk5xSoJDWoSJGkKwq1aJFYs1jRmQXDBaY5QjlYmiFHzjNFL0yxmgLVpc8HwN3BIvv18wWY0mKp8O5QQfEmMU3SJdjML5cEUJ1VO1xoI7cAlTRAVFO1qhrmsOguOT3qnxweO3W2Byf1pbdwEk-71kohGUuhS4DowdyNcW50iBryuMPWMmOAcYkUJ9OBkClPbBJxmbA00t49spXPcvOAQFsVAFMmwjW-YMooN7KuFxklmfXSgHcIa_o2TmspdMzIMY3LKVEo4woaMZxHXEIjjjrk5brO10oI5L_WBwiZtSWKeJc_zObncT0mxDzQSisR6CDSIkH1K2utp7zQlwa4hd8hzxBwMYIfTg96r9oxAY1E0a64J6NIoGAcNGivZQlDRNoubiAbNx4GRwf2InyOx3myLsaauOwuN4CImEsOlx4on-yQ-xXC101qHKVDghb2W21ul-TZl1LAPAxFGAn-8J__-Yjs8tItucPkHtkCHzCPgfwtVJdsBpOgS7Z7veHnIbwf9McfP3XLWynw-n7CuqXP_wGG6F3G |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGJgEviDuFAUYCAZqixY7jJEgI7aqVbQWhbtqbiWN7RNrS0bRC5UftR_B7-BGck0u3CGlve2vr48on_nwusf0dQl6zVEc8hRkIXeB7Ar542sXMCzMm0cE7J_CC8_5A7hyIz0fh0QI5b-_C4LHK1iZWhtqMMnxHvgpu1g8EpE3hp7OfHlaNwt3VtoRGDYtdO_sFKVv5sb8J8_uG8-2t4caO11QV8LJQBhMvDYzvnBSSsQwcGAQUkCMwzq2Jkascb3I6Zi14dpFh0hYJmfHUpQmXKcsSE8D_3iBLIoBQYZEsrW8Nvn6b71tEsRTt1ZxYrpbgIap9Uu75kDeEXtJxf1WVgP99wSVn2D2oecnzbd8ld5qQla7VGLtHFmxxn9zcbzblH5C_ADXaHxxuDYZ048thf5NWpUA-0JTW7LTTsTUUCSFGgDoKUTK0gIs0o9P8N7Q0p-VP4GPVkeYX3B_FMYUIlVokukizGYVetEydnczoyIHgBKsnIcsszTH0LnJNT205O4EImr7rQ0oAEvmf8_cgSsupxpdOJcV3zzTNpiAzvjhpQE1eX5yhLYsDdDKAfEP1rFbMY8lDcnAt0_2ILBajwj4hoKsGvMtU-DYUTFvtJ84PEqslc0EW8R5h7dyqrGFYx0IfJ6rKtGKpajwoGIeq8KCSHlmZ9zmr-UWulF5HyMwlkRu8-mE0PlaNqVE8MtpoEZkoMSJFUi3nXKCDOJQWQpawR94i4BRaMBgezF59EQOURC4wtSaTRCAPHSi03JEEy5N1m1vIqsbylepinfbIq3kz9sTTfIUFRCguOTx6iCRljzyuET5XKQixYlrCeiTqYL-jc7elyH9UvOhxLOJE8KdXD-slubUz3N9Te_3B7jNym1eLk3tMLpNFWBT2OQSZE_2iWdmUfL9uY_IP-1CQfA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkCZeEHcCA4wEAoSixY7jJEgIjV20MlZ42Ka-eXFsj0hbOppOqPwofgCP_B5-BOfk0i5C2tve2vq4suPv3Bz7O4S8YJmOeQYrELkw8AV88bVLmB_lTKKDd07gBee9odw5EJ9G0WiJ_O7uwuCxys4m1obajHPcI18DNxuEAtKmaM21xyK-bm5_OPvuYwUpfNPaldNoILJrZz8gfaveDzZhrV9yvr21v7HjtxUG_DyS4dTPQhM4J4VkLAdnBsEF5AuMc2sS5C3HW52OWQteXuSYwMVC5jxzWcplxvLUhPC_18j1OIROoEvxaJ7ssTiRorukk8i1CnxF_caU-wFkEJGf9hxhXS_gf69wwS32j2xe8IHbt8jNNnil6w3abpMlW94hK3vt6_m75C-Ajg6Gh1vDfbrx5XCwSeuiIO9oRhue2vOJNRSpIcaAPwrxMrSAszTj0-IntLTn5k_gY92RFgsWkPKYQqxKLVJeZPmMQi9aZc5OZ3TsQHCKdZSQb5YWGISXhaantpqdQCxNXw8gOQCJ4s-vNyBKq3ON208VxV1omuXnIDNZnDmgpmiu0NCOzwE6GdABQ_WsmZjP0nvk4EoW-z5ZLselfUhgrhqQLzMR2EgwbXWQuiBMrZbMhXnMPcK6tVV5y7WOJT9OVJ1zJVI1eFAwDlXjQaUeeTvvc9YwjVwq_REhM5dElvD6h_HkWLVGR_HYaKNFbOLUiAzptZxzoQ6TSFoIXiKPvELAKbRlMDxYveZKBkwSWcHUukxTgYx0MKHVniTYoLzf3EFWtTawUguN9cjzeTP2xHN9pQVEKC45PHqIKaVHHjQIn08JlCrmSco8Evew35tzv6UsvtUM6UkiklTwR5cP6xlZAROiPg-Gu4_JDV7rJveZXCXLoBP2CUSbU_20VmtKjq7ajvwD-4iTTA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+INVENT+COVID+trial%3A+a+structured+protocol+for+a+randomized+controlled+trial+investigating+the+efficacy+and+safety+of+intravenous+imatinib+mesylate+%28Impentri%C2%AE%29+in+subjects+with+acute+respiratory+distress+syndrome+induced+by+COVID-19&rft.jtitle=Trials&rft.au=Atmowihardjo%2C+Leila&rft.au=Schippers%2C+Job+R&rft.au=Bartelink%2C+Imke+H&rft.au=Bet%2C+Pierre+M&rft.date=2022-02-16&rft.eissn=1745-6215&rft.volume=23&rft.issue=1&rft.spage=158&rft_id=info:doi/10.1186%2Fs13063-022-06055-9&rft_id=info%3Apmid%2F35172891&rft.externalDocID=35172891 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |